baseline ultrasound scans were performed on the same day. Recombinant follicle-stimulating hormone (rFSH) (Gonal-F ® ; Merck Serono, Switzerland) was used for ovarian stimulation at a dosage of 225 IU daily. From the fifth day of rFSH therapy onwards, patient was monitored daily or every other day for hormone levels (oestradiol, LH, and progesterone whenever needed) and follicular measurements. The stimulation protocol was as outlined previously. 1,2 A daily administration of 0.25 mg GnRH antagonist (Cetrotide ® ; Merck Serono) was started when the follicle reached 12-13 mm in size. Follicular maturation was achieved using 250 µg recombinant human chorionic gonadotropin (hCG) (Ovitrelle ® ; Merck Serono) when at least three follicles reached a minimum mean diameter of 17 mm. Transvaginal ultrasound-guided oocyte retrieval was scheduled after 36 h. However, she informed us on OPU day that her husband had been hospitalized following a car crush in Albania and was unable to travel to our clinic to give a sperm sample. We were therefore placed in the position of having to make an emergency decision. OPU was done, and seven oocytes were retrieved. Six metaphase II (MII) oocytes out of seven cumulus-enclosed oocyte complexes (COCs) were vitrified using the Kitazato Vitrification Cryotop Kit (Kitazato, Japan) according to the manufacturer's instructions. [3] [4] [5] [6] [7] After 6 months, in November 2013, the patient applied for transfer. Written informed consent was obtained from husband and wife before thawing the frozen oocytes to be used for intracytoplasmic sperm injection (ICSI) procedure. Her endometrium was prepared with 2 mg oestradiol valerate three times per day (total dose: 6 mg). On Day 14 of the cycle, the endometrial thickness was 11 mm and the frozen oocytes were thawed according to the manufacturer's instructions of the Kitazato Thawing Kit (Kitazato). Warmed oocytes were incubated for 2 h, and five surviving oocytes with normal morphology ( Figure 1) were injected with the husband's fresh sperm. Figure 2 shows five frozen-thawed MII oocytes analysed by polarized microscopy before ICSI.
Of the developed four zygotes, three were classified as good quality embryos on Day 3. The embryos were monitored using a time-lapse incubator (EmbryoScope™ timelapse system; Vitrolife, Sweden). Figure 3 shows the timeline of the five thawed oocytes incubated in EmbryoScope until Day 4 (oocyte nos 2 and 3 were further transferred).
On Day 5, two blastocysts (4BB and 2AA) were transferred ( Figure 4) . Luteal phase was supported with progesterone 8% gel (Crinone ® 8%; Merck Serono) twice daily starting on the 14th day of the cycle. The ART trial resulted with a singleton pregnancy and the birth of a healthy newborn at term via caesarean section.
Discussion
To our knowledge, this is the first successful birth after a pregnancy achieved using vitrified-warm oocytes in Turkey. The story of our couple includes complex aspects of infertility including ovarian cyst, pelvic infection, induced abortion, missed abortion, dilatation and curettage, laparoscopy, laparotomy, OPU, oocyte vitrification, embryo transfer and To return to the case in question, on the day of OPU, the patient informed us that her husband had been hospitalized following a car crush in Albania and was unable to travel to our clinic to give sperm sample. We were therefore placed in the position of having to make an emergency decision. Should we allow the patient to lose this chance of a pregnancy at her 10th ART attempt by allowing spontaneous ovulation and loss of her eggs or should we allow her the chance of a future pregnancy by freezing the eggs. Unfortunately, the wording of the regulations did not specifically address this unexpected emergency situation. We saw our decision to cryopreserve the oocytes as a valid interpretation of the regulations, bearing in mind also the requirement that sperm and oocyte in the in vitro fertilization (IVF) process must be those of a married couple.
In 2014, a Committee on Gynaecologic Practice Opinion from the American College of Obstetricians (ACOG) and Gynaecologists supported the 2013 joint document of the American Society for Reproductive Medicine and the Society for Reproductive Technology and suggested that oocyte vitrification would no longer be considered experimental. 10 In Turkey, regulations on oocyte cryopreservation have similarities with the ACOG Committee Opinion and they are included in the 'Regulation Codes on Assisted Reproductive Procedures and ART Centres' 9 redesigned in 2014 by the Turkish Ministry of Health.
According to the code, the cryopreservation of oocytes or ovarian tissues is permitted only in the following medical circumstances as documented by a panel of three specialist doctors: prior to treatments such as chemotherapy or radiotherapy which may damage reproductive cells; prior to surgery such as the removal of the ovaries which may result in the loss of reproductive functions; in cases of low ovarian reserve where the woman is childless or there is a family history of early menopause.
In cases where the immediate need for essential oocyte cryopreservation arises, regulations do not sufficiently describe the options. For example, as in the case of our patient, a difficulty may arise when a married couple has undergone preparation for ART but an unexpected social/ personal or medical event intervenes at a critical point, resulting in uncertainty over whether or not oocytes may or may not be frozen for use at an appropriate future time. Our patient, despite a very complex and complicated medical history, gave birth to a healthy child at the 10th ART attempt. If her oocytes had not been frozen, she would have lost the chance of a pregnancy resulting from this cycle. It is therefore extremely important that regulations should be amended to describe emergency situations.
Regulation codes in Turkey allow oocyte vitrification in cases where medical and/or surgical procedures jeopardize the existence of female reproductive cells and in single women with a family history of early menopause or diminished ovarian reserve. However, it is not clear whether married women with similar conditions may also benefit from the regulation. As an example, can married women with diminished ovarian reserve and wishing to postpone pregnancy use the oocyte cryopreservation option? It is well known that there is a close correlation between female age, a higher number of obtained oocytes, the successful freezing of oocytes, and higher chances of pregnancy. 6, 7 Therefore, why should not women with high ovarian reserve be offered oocyte vitrification in order to allow for better clinical outcomes in the future. The limitation of the freezing of oocytes to cases of low ovarian reserve, where outcomes are much less likely to be successful, should be reconsidered.
In conclusion, using vitrified/thawed oocytes has comparable clinical outcomes with using fresh oocytes in ART. However, Turkish medicolegal regulations should be revised to increase the chances of more women taking advantage of the procedure to preserve their reproductive autonomy and to give guidance on what action may be taken in emergency situations.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
Ethical approval
Our institution does not require ethical approval for reporting individual cases or case series.
Funding
The author(s) received no financial support for the research, authorship and/or publication of this article.
Informed consent
Written informed consent was obtained from the patient(s) for their anonymized information to be published in this article.
